DK2877177T3 - Derivater af azaindazol- eller diazaindazol-type til behandling af smerte - Google Patents
Derivater af azaindazol- eller diazaindazol-type til behandling af smerte Download PDFInfo
- Publication number
- DK2877177T3 DK2877177T3 DK13745813.9T DK13745813T DK2877177T3 DK 2877177 T3 DK2877177 T3 DK 2877177T3 DK 13745813 T DK13745813 T DK 13745813T DK 2877177 T3 DK2877177 T3 DK 2877177T3
- Authority
- DK
- Denmark
- Prior art keywords
- charom
- pain
- group
- mmol
- compound
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 107
- 230000036407 pain Effects 0.000 title claims description 97
- 238000011282 treatment Methods 0.000 title claims description 29
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 57
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 11
- 208000004296 neuralgia Diseases 0.000 claims description 11
- 208000021722 neuropathic pain Diseases 0.000 claims description 11
- 206010065390 Inflammatory pain Diseases 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 5
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000028389 Nerve injury Diseases 0.000 claims description 4
- 230000008764 nerve damage Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 235000019256 formaldehyde Nutrition 0.000 claims description 3
- 230000001107 psychogenic effect Effects 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 179
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 165
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 149
- 238000000034 method Methods 0.000 description 144
- 239000000243 solution Substances 0.000 description 139
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 118
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 93
- 239000007787 solid Substances 0.000 description 90
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 88
- 238000005160 1H NMR spectroscopy Methods 0.000 description 81
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 77
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 74
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 70
- 239000012429 reaction media Substances 0.000 description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000002904 solvent Substances 0.000 description 64
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 62
- 238000006243 chemical reaction Methods 0.000 description 61
- 239000012074 organic phase Substances 0.000 description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 52
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 238000010586 diagram Methods 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 48
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 45
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 35
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 235000019341 magnesium sulphate Nutrition 0.000 description 33
- -1 diazaindazole compound Chemical class 0.000 description 32
- 238000003756 stirring Methods 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 239000002798 polar solvent Substances 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000010898 silica gel chromatography Methods 0.000 description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- 239000002244 precipitate Substances 0.000 description 19
- 239000007795 chemical reaction product Substances 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 15
- 150000007529 inorganic bases Chemical class 0.000 description 15
- 150000007530 organic bases Chemical class 0.000 description 15
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 14
- 108010025020 Nerve Growth Factor Proteins 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 13
- 102000015336 Nerve Growth Factor Human genes 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 13
- 229940053128 nerve growth factor Drugs 0.000 description 13
- 101150111783 NTRK1 gene Proteins 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 11
- 208000004454 Hyperalgesia Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 101150056950 Ntrk2 gene Proteins 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 230000003197 catalytic effect Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- XVIHGTRTKQZJAC-UHFFFAOYSA-N 6-chloro-3-nitropyridine-2-carbonitrile Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1C#N XVIHGTRTKQZJAC-UHFFFAOYSA-N 0.000 description 7
- 208000000094 Chronic Pain Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002038 ethyl acetate fraction Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- BYEUNDASYOFKIW-UHFFFAOYSA-N 5-iodo-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical class C1=C(I)C=C2C(N)=NNC2=N1 BYEUNDASYOFKIW-UHFFFAOYSA-N 0.000 description 6
- 206010005949 Bone cancer Diseases 0.000 description 6
- 208000018084 Bone neoplasm Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 229910020008 S(O) Inorganic materials 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical class C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 description 5
- JPGXJOYWNKSCGX-UHFFFAOYSA-N 2-[(4,4-difluorocyclohexyl)-(2,2,2-trifluoroacetyl)amino]-4-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C(N(C2CCC(F)(F)CC2)C(=O)C(F)(F)F)=C1 JPGXJOYWNKSCGX-UHFFFAOYSA-N 0.000 description 5
- UQNVAKOELHOJFN-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-4-ium-1-yl)phenyl]acetate Chemical compound C1CN(C)CCN1C1=CC=C(CC(O)=O)C=C1 UQNVAKOELHOJFN-UHFFFAOYSA-N 0.000 description 5
- FYHRQFFVACXNTB-UHFFFAOYSA-N 2-chloro-5-iodopyridine-3-carbonitrile Chemical class ClC1=NC=C(I)C=C1C#N FYHRQFFVACXNTB-UHFFFAOYSA-N 0.000 description 5
- IHWZCGMZILLKFD-UHFFFAOYSA-N 2-methoxypyridine-3-carbonitrile Chemical compound COC1=NC=CC=C1C#N IHWZCGMZILLKFD-UHFFFAOYSA-N 0.000 description 5
- GPYNAAUDGBICPV-UHFFFAOYSA-N 3-amino-n-(3,5-difluorophenyl)-2h-pyrazolo[3,4-b]pyridine-5-sulfonamide Chemical compound C1=C2C(N)=NNC2=NC=C1S(=O)(=O)NC1=CC(F)=CC(F)=C1 GPYNAAUDGBICPV-UHFFFAOYSA-N 0.000 description 5
- JVIGDQVFRFSUKJ-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methoxy]-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=C2C(N)=NNC2=NC=C1OCC1=CC(F)=CC(F)=C1 JVIGDQVFRFSUKJ-UHFFFAOYSA-N 0.000 description 5
- KAXIYYPIORYZLB-UHFFFAOYSA-N 5-hydroxypyridine-3-carbonitrile Chemical class OC1=CN=CC(C#N)=C1 KAXIYYPIORYZLB-UHFFFAOYSA-N 0.000 description 5
- XXMSBZGWGCYUDN-UHFFFAOYSA-N 5-iodo-2h-pyrazolo[3,4-b]pyrazin-3-amine Chemical compound C1=C(I)N=C2C(N)=NNC2=N1 XXMSBZGWGCYUDN-UHFFFAOYSA-N 0.000 description 5
- OYXUUECJEFKKLG-UHFFFAOYSA-N 5-iodo-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound NC1=C(I)C=C2C(N)=NNC2=N1 OYXUUECJEFKKLG-UHFFFAOYSA-N 0.000 description 5
- JWRYNLANQMKICK-UHFFFAOYSA-N 6-(2,4-difluoroanilino)-2-methylsulfanylpyridine-3-carbonitrile Chemical compound C1=C(C#N)C(SC)=NC(NC=2C(=CC(F)=CC=2)F)=C1 JWRYNLANQMKICK-UHFFFAOYSA-N 0.000 description 5
- IOCCJZXMIMJYOD-UHFFFAOYSA-N 6-(2,4-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=1C=C2C(N)=NNC2=NC=1SC1=CC=C(F)C=C1F IOCCJZXMIMJYOD-UHFFFAOYSA-N 0.000 description 5
- JUVQPYNYLHZBKI-UHFFFAOYSA-N 6-n-(2,4-difluorophenyl)-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=1C=C2C(N)=NNC2=NC=1NC1=CC=C(F)C=C1F JUVQPYNYLHZBKI-UHFFFAOYSA-N 0.000 description 5
- APASLXZZEDBGED-UHFFFAOYSA-N 6-n-(2,4-difluorophenyl)-6-n-methyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=1C=C2C(N)=NNC2=NC=1N(C)C1=CC=C(F)C=C1F APASLXZZEDBGED-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 208000035154 Hyperesthesia Diseases 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- FMLZEDJKDLHEAY-UHFFFAOYSA-N n-(3-amino-2h-pyrazolo[3,4-b]pyridin-5-yl)-3,5-difluorobenzenesulfonamide Chemical compound C1=C2C(N)=NNC2=NC=C1NS(=O)(=O)C1=CC(F)=CC(F)=C1 FMLZEDJKDLHEAY-UHFFFAOYSA-N 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 235000011150 stannous chloride Nutrition 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 5
- XMRKFDSPGSPFGE-UHFFFAOYSA-N (5-cyano-6-methylsulfanylpyridin-2-yl) trifluoromethanesulfonate Chemical compound CSC1=NC(OS(=O)(=O)C(F)(F)F)=CC=C1C#N XMRKFDSPGSPFGE-UHFFFAOYSA-N 0.000 description 4
- UVKBAINRDCMDIE-UHFFFAOYSA-N 2,2,2-trichloro-1-[4-(4-methylpiperazin-1-yl)phenyl]ethanol Chemical compound C1CN(C)CCN1C1=CC=C(C(O)C(Cl)(Cl)Cl)C=C1 UVKBAINRDCMDIE-UHFFFAOYSA-N 0.000 description 4
- VVKFXPRMHQRBGL-UHFFFAOYSA-N 2-amino-5-cyano-6-methylsulfanylpyridine-3-carboxylic acid Chemical compound CSC1=NC(N)=C(C(O)=O)C=C1C#N VVKFXPRMHQRBGL-UHFFFAOYSA-N 0.000 description 4
- PLERTPJDYXYVTI-UHFFFAOYSA-N 2-chloro-5-[(3,5-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC(COC=2C=C(C(Cl)=NC=2)C#N)=C1 PLERTPJDYXYVTI-UHFFFAOYSA-N 0.000 description 4
- MCPVFSJAPYCXMS-UHFFFAOYSA-N 2-chloro-5-[(3,5-difluorophenyl)sulfamoyl]pyridine-3-carboxamide Chemical compound N1=C(Cl)C(C(=O)N)=CC(S(=O)(=O)NC=2C=C(F)C=C(F)C=2)=C1 MCPVFSJAPYCXMS-UHFFFAOYSA-N 0.000 description 4
- PTDOCINOKMDHSU-UHFFFAOYSA-N 2-chloro-6-(2,4-difluorophenyl)sulfanylpyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1SC1=CC=C(C#N)C(Cl)=N1 PTDOCINOKMDHSU-UHFFFAOYSA-N 0.000 description 4
- WUAWAZWIWVBBEM-UHFFFAOYSA-N 3-amino-6-iodopyrazine-2-carbonitrile Chemical compound NC1=NC=C(I)N=C1C#N WUAWAZWIWVBBEM-UHFFFAOYSA-N 0.000 description 4
- QDHZJXAAFQGWIY-UHFFFAOYSA-N 3-amino-6-iodopyrazine-2-carboxamide Chemical class NC(=O)C1=NC(I)=CN=C1N QDHZJXAAFQGWIY-UHFFFAOYSA-N 0.000 description 4
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 4
- UFTSPZWLJMPOKT-UHFFFAOYSA-N 3-chloro-6-iodopyrazine-2-carbonitrile Chemical compound ClC1=NC=C(I)N=C1C#N UFTSPZWLJMPOKT-UHFFFAOYSA-N 0.000 description 4
- FHHKMGLAIOHCQY-UHFFFAOYSA-N 3-nitro-6-sulfanylidene-1h-pyridine-2-carbonitrile Chemical compound [O-][N+](=O)C=1C=CC(=S)NC=1C#N FHHKMGLAIOHCQY-UHFFFAOYSA-N 0.000 description 4
- UVSUWPMFLDLVMI-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzaldehyde Chemical compound C1CN(C)CCN1C1=CC=C(C=O)C(NC2CCOCC2)=C1 UVSUWPMFLDLVMI-UHFFFAOYSA-N 0.000 description 4
- XDBOLUQMQARCQO-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)sulfanyl-1h-pyrazolo[4,3-b]pyridin-3-amine Chemical compound N1=C2C(N)=NNC2=CC=C1SC1=CC(Cl)=CC(Cl)=C1 XDBOLUQMQARCQO-UHFFFAOYSA-N 0.000 description 4
- RVLCKYBNAYDRIJ-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyrazin-3-amine Chemical compound N1=C2C(N)=NNC2=NC=C1SC1=CC(F)=CC(F)=C1 RVLCKYBNAYDRIJ-UHFFFAOYSA-N 0.000 description 4
- BMYJZWWKUPNCNN-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methoxy]-1-oxidopyridin-1-ium-3-carbonitrile Chemical compound N#CC1=C[N+]([O-])=CC(OCC=2C=C(F)C=C(F)C=2)=C1 BMYJZWWKUPNCNN-UHFFFAOYSA-N 0.000 description 4
- ABNOQRUXVJFBSN-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC(COC=2C=C(C=NC=2)C#N)=C1 ABNOQRUXVJFBSN-UHFFFAOYSA-N 0.000 description 4
- VGYONHCACXTVFA-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methylsulfanyl]-1h-pyrazolo[4,3-b]pyridin-3-amine Chemical compound N1=C2C(N)=NNC2=CC=C1SCC1=CC(F)=CC(F)=C1 VGYONHCACXTVFA-UHFFFAOYSA-N 0.000 description 4
- FRKLCMNRGGZZTQ-UHFFFAOYSA-N 5-bromo-2-methoxypyridine-3-carbonitrile Chemical compound COC1=NC=C(Br)C=C1C#N FRKLCMNRGGZZTQ-UHFFFAOYSA-N 0.000 description 4
- SSNUTEUZXZIYTB-UHFFFAOYSA-N 5-bromo-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound N1=CC(Br)=CC2=C(N)NN=C21 SSNUTEUZXZIYTB-UHFFFAOYSA-N 0.000 description 4
- DHWIFHCOMJIINQ-UHFFFAOYSA-N 5-cyano-6-methylsulfanyl-2-oxo-1h-pyridine-3-carboxylic acid Chemical compound CSC=1NC(=O)C(C(O)=O)=CC=1C#N DHWIFHCOMJIINQ-UHFFFAOYSA-N 0.000 description 4
- DHNUUSNUUZTHEN-UHFFFAOYSA-N 5-iodo-2-oxo-1h-pyridine-3-carbonitrile Chemical compound IC1=CNC(=O)C(C#N)=C1 DHNUUSNUUZTHEN-UHFFFAOYSA-N 0.000 description 4
- CNTGLVVONIKHSF-UHFFFAOYSA-N 5-iodo-6-methoxy-2-methylsulfanylpyridine-3-carbonitrile Chemical compound COC1=NC(SC)=C(C#N)C=C1I CNTGLVVONIKHSF-UHFFFAOYSA-N 0.000 description 4
- KSGXFRBLXNHRNM-UHFFFAOYSA-N 5-iodo-6-methoxy-2-methylsulfinylpyridine-3-carbonitrile Chemical compound COC1=NC(S(C)=O)=C(C#N)C=C1I KSGXFRBLXNHRNM-UHFFFAOYSA-N 0.000 description 4
- DZGYLSFTOFCXFZ-UHFFFAOYSA-N 5-iodo-6-methoxy-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=C(I)C(OC)=NC2=C1C(N)=NN2 DZGYLSFTOFCXFZ-UHFFFAOYSA-N 0.000 description 4
- ODCXTIKFDHBSQN-UHFFFAOYSA-N 6-amino-5-iodo-2-methylsulfinylpyridine-3-carbonitrile Chemical compound CS(=O)C1=NC(N)=C(I)C=C1C#N ODCXTIKFDHBSQN-UHFFFAOYSA-N 0.000 description 4
- IMSRXABOKDAELG-UHFFFAOYSA-N 6-chloro-5-cyano-n-(3,5-difluorophenyl)pyridine-3-sulfonamide Chemical compound FC1=CC(F)=CC(NS(=O)(=O)C=2C=C(C(Cl)=NC=2)C#N)=C1 IMSRXABOKDAELG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- VMMMYBOZMXKJMU-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)phenyl]methanol Chemical compound C1CN(C)CCN1C1=CC=C(CO)C(NC2CCOCC2)=C1 VMMMYBOZMXKJMU-UHFFFAOYSA-N 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 239000012223 aqueous fraction Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- PFNXTASHNOUFCN-UHFFFAOYSA-N ethyl 2-amino-5-cyano-6-methylsulfanylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(SC)N=C1N PFNXTASHNOUFCN-UHFFFAOYSA-N 0.000 description 4
- UCDROSIPSKGDQH-UHFFFAOYSA-N ethyl 5-cyano-6-methylsulfanyl-2-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(SC)N=C1O UCDROSIPSKGDQH-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- FDLARAKNPMCCKJ-UHFFFAOYSA-N methyl 3-amino-6-iodopyrazine-2-carboxylate Chemical compound COC(=O)C1=NC(I)=CN=C1N FDLARAKNPMCCKJ-UHFFFAOYSA-N 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- DDDZNRSTGCSUJP-UHFFFAOYSA-N n'-(3-cyano-5-iodopyrazin-2-yl)-n,n-dimethylmethanimidamide Chemical compound CN(C)C=NC1=NC=C(I)N=C1C#N DDDZNRSTGCSUJP-UHFFFAOYSA-N 0.000 description 4
- JDPQOPNYABKMJI-UHFFFAOYSA-N n-(6-chloro-5-cyanopyridin-3-yl)-3,5-difluorobenzenesulfonamide Chemical compound FC1=CC(F)=CC(S(=O)(=O)NC=2C=C(C(Cl)=NC=2)C#N)=C1 JDPQOPNYABKMJI-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 239000012454 non-polar solvent Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- DXXKATNBNNUIAW-UHFFFAOYSA-N 1-(4-isothiocyanatophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(N=C=S)C=C1 DXXKATNBNNUIAW-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- ANHONFDXFZTKAC-UHFFFAOYSA-N 1-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-yl]-3-[4-(4-methylpiperazin-1-yl)phenyl]urea Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)NC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 ANHONFDXFZTKAC-UHFFFAOYSA-N 0.000 description 3
- LFCADBSUDWERJT-UHFFFAOYSA-N 2,6-dichloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=N1 LFCADBSUDWERJT-UHFFFAOYSA-N 0.000 description 3
- SIGRPFDCVORHOW-UHFFFAOYSA-N 2-(4-aminophenyl)-n-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-yl]acetamide Chemical compound C1=CC(N)=CC=C1CC(=O)NC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 SIGRPFDCVORHOW-UHFFFAOYSA-N 0.000 description 3
- UAFHMAWFIOXXQI-NSHDSACASA-N 2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]-4-[(3s)-3-[(2,2,2-trifluoroacetyl)amino]pyrrolidin-1-yl]benzoic acid Chemical compound OC(=O)C1=CC=C(N2C[C@H](CC2)NC(=O)C(F)(F)F)C=C1N(C(=O)C(F)(F)F)C1CCOCC1 UAFHMAWFIOXXQI-NSHDSACASA-N 0.000 description 3
- YCNQPAVKQPLZRS-UHFFFAOYSA-N 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical class O1C(C)(C)C(C)(C)OB1CC1=CC=CC=C1 YCNQPAVKQPLZRS-UHFFFAOYSA-N 0.000 description 3
- MOUURCSKHKVYPB-UHFFFAOYSA-N 2-methylsulfanyl-6-oxo-1h-pyridine-3-carbonitrile Chemical compound CSC1=NC(O)=CC=C1C#N MOUURCSKHKVYPB-UHFFFAOYSA-N 0.000 description 3
- NUEYBFIIUBXAHT-UHFFFAOYSA-N 3-amino-6-(3,5-dichlorophenyl)sulfanylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(N)=CC=C1SC1=CC(Cl)=CC(Cl)=C1 NUEYBFIIUBXAHT-UHFFFAOYSA-N 0.000 description 3
- PAUUZIXIERHUHC-UHFFFAOYSA-N 3-amino-6-(3,5-difluoroanilino)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(N)=CC=C1NC1=CC(F)=CC(F)=C1 PAUUZIXIERHUHC-UHFFFAOYSA-N 0.000 description 3
- WRQYZMAMPGGLGG-UHFFFAOYSA-N 3-amino-6-[(3,5-difluorophenyl)methylsulfanyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(N)=CC=C1SCC1=CC(F)=CC(F)=C1 WRQYZMAMPGGLGG-UHFFFAOYSA-N 0.000 description 3
- OXQLRGICXLDZGZ-UHFFFAOYSA-N 3-amino-6-[(3,5-difluorophenyl)methylsulfanyl]pyridine-2-carboxamide Chemical compound C1=C(N)C(C(=O)N)=NC(SCC=2C=C(F)C=C(F)C=2)=C1 OXQLRGICXLDZGZ-UHFFFAOYSA-N 0.000 description 3
- DYUMBFTYRJMAFK-UHFFFAOYSA-N 3-cyano-2-pyridone Chemical compound OC1=NC=CC=C1C#N DYUMBFTYRJMAFK-UHFFFAOYSA-N 0.000 description 3
- UXJJKFGTQCOPTI-NSHDSACASA-N 4-[(3s)-3-aminopyrrolidin-1-yl]-2-(oxan-4-ylamino)benzoic acid Chemical compound C1[C@@H](N)CCN1C1=CC=C(C(O)=O)C(NC2CCOCC2)=C1 UXJJKFGTQCOPTI-NSHDSACASA-N 0.000 description 3
- SIRWWTJTGFJUNU-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfanyl-n-[[4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)phenyl]methyl]-1h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1CNC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 SIRWWTJTGFJUNU-UHFFFAOYSA-N 0.000 description 3
- ANCBPIWGSUPBAJ-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfinyl-2h-pyrazolo[3,4-b]pyrazin-3-amine Chemical compound N1=C2C(N)=NNC2=NC=C1S(=O)C1=CC(F)=CC(F)=C1 ANCBPIWGSUPBAJ-UHFFFAOYSA-N 0.000 description 3
- RKJLJEWNXQZBIX-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfonyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=C2C(N)=NNC2=NC=C1S(=O)(=O)C1=CC(F)=CC(F)=C1 RKJLJEWNXQZBIX-UHFFFAOYSA-N 0.000 description 3
- YEFREPQOEYTXHU-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methyl]-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=C2C(N)=NNC2=NC=C1CC1=CC(F)=CC(F)=C1 YEFREPQOEYTXHU-UHFFFAOYSA-N 0.000 description 3
- RGFRMTNTNUBPQX-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)sulfamoyl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(S(=O)(=O)NC=2C=C(F)C=C(F)C=2)=C1 RGFRMTNTNUBPQX-UHFFFAOYSA-N 0.000 description 3
- ZEXJVDQSKVHQKM-UHFFFAOYSA-N 5-n-(3,5-difluorophenyl)-1h-pyrazolo[4,3-b]pyridine-3,5-diamine Chemical compound N1=C2C(N)=NNC2=CC=C1NC1=CC(F)=CC(F)=C1 ZEXJVDQSKVHQKM-UHFFFAOYSA-N 0.000 description 3
- PLRDSYYAKHJRON-UHFFFAOYSA-N 6-[(3,5-difluorophenyl)methyl]-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=1C=C2C(N)=NNC2=NC=1CC1=CC(F)=CC(F)=C1 PLRDSYYAKHJRON-UHFFFAOYSA-N 0.000 description 3
- BJVTVMIGYUTGED-UHFFFAOYSA-N 6-[(3,5-difluorophenyl)methylsulfanyl]-3-nitropyridine-2-carbonitrile Chemical compound N1=C(C#N)C([N+](=O)[O-])=CC=C1SCC1=CC(F)=CC(F)=C1 BJVTVMIGYUTGED-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000000297 Sandmeyer reaction Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000007033 dehydrochlorination reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002429 hydrazines Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 3
- 230000026045 iodination Effects 0.000 description 3
- 238000006192 iodination reaction Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- KCHLSEMOIQITKI-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyrazin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC1=C2N=C(SC=3C=C(F)C=C(F)C=3)C=NC2=NN1 KCHLSEMOIQITKI-UHFFFAOYSA-N 0.000 description 3
- ZGGJRARKGWGFIA-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzamide Chemical compound C1CN(C)CCN1C(C=C1N(C2CCOCC2)C(=O)C(F)(F)F)=CC=C1C(=O)NC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 ZGGJRARKGWGFIA-UHFFFAOYSA-N 0.000 description 3
- QPQVPVSYRKEUAZ-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-6-oxo-1,2-dihydropyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=NC(O)=C2SC1=CC(F)=CC(F)=C1 QPQVPVSYRKEUAZ-UHFFFAOYSA-N 0.000 description 3
- GTJRZXUZLSBJFN-UHFFFAOYSA-N n-[5-[2-(3,5-difluorophenyl)ethyl]-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=NC=C2CCC1=CC(F)=CC(F)=C1 GTJRZXUZLSBJFN-UHFFFAOYSA-N 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000005229 pyrazolopyridines Chemical class 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DFSGLWKPJNAHSD-UHFFFAOYSA-N tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate Chemical compound C1CN(C)CCC1C1=CC=C(C(=O)OC(C)(C)C)C(N)=C1 DFSGLWKPJNAHSD-UHFFFAOYSA-N 0.000 description 3
- ZHNMVTLHFLSTHK-UHFFFAOYSA-N tert-butyl 2-nitro-4-pyridin-4-ylbenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC(C)(C)C)=CC=C1C1=CC=NC=C1 ZHNMVTLHFLSTHK-UHFFFAOYSA-N 0.000 description 3
- JNHYZIQVZUSMAB-UHFFFAOYSA-N tert-butyl 4-(1-methylpiperidin-4-yl)-2-(oxan-4-ylamino)benzoate Chemical compound C1CN(C)CCC1C1=CC=C(C(=O)OC(C)(C)C)C(NC2CCOCC2)=C1 JNHYZIQVZUSMAB-UHFFFAOYSA-N 0.000 description 3
- FEWNHXSFBOSNBZ-UHFFFAOYSA-M tert-butyl 4-(1-methylpyridin-1-ium-4-yl)-2-nitrobenzoate;iodide Chemical compound [I-].C1=C[N+](C)=CC=C1C1=CC=C(C(=O)OC(C)(C)C)C([N+]([O-])=O)=C1 FEWNHXSFBOSNBZ-UHFFFAOYSA-M 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- NMEPLWZDUIIAAC-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridazine Chemical class C1=NN=C2C=NNC2=C1 NMEPLWZDUIIAAC-UHFFFAOYSA-N 0.000 description 2
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical group C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical class [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 2
- OUHBWOIKQHDTAD-UHFFFAOYSA-N 2-(2-fluoroethoxy)-4-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C(OCCF)=C1 OUHBWOIKQHDTAD-UHFFFAOYSA-N 0.000 description 2
- QKYVZDRYXYVJBZ-UHFFFAOYSA-N 2-[2-fluoroethyl-(2,2,2-trifluoroacetyl)amino]-4-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C(N(CCF)C(=O)C(F)(F)F)=C1 QKYVZDRYXYVJBZ-UHFFFAOYSA-N 0.000 description 2
- WBWGUECQZSTJSY-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)-2-nitrophenyl]acetic acid Chemical compound C1CN(C)CCN1C1=CC=C(CC(O)=O)C([N+]([O-])=O)=C1 WBWGUECQZSTJSY-UHFFFAOYSA-N 0.000 description 2
- JAUPUQRPBNDMDT-UHFFFAOYSA-N 2-chloropyridine-3-carbonitrile Chemical compound ClC1=NC=CC=C1C#N JAUPUQRPBNDMDT-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- KQOIBXZRCYFZSO-UHFFFAOYSA-N 3,5-difluoroaniline Chemical compound NC1=CC(F)=CC(F)=C1 KQOIBXZRCYFZSO-UHFFFAOYSA-N 0.000 description 2
- WKPKXPORUZFLMM-UHFFFAOYSA-N 4-(1-methylpiperidin-4-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound C1CN(C)CCC1C1=CC=C(C(O)=O)C(N(C2CCOCC2)C(=O)C(F)(F)F)=C1 WKPKXPORUZFLMM-UHFFFAOYSA-N 0.000 description 2
- PFODEVGLOVUVHS-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(C)CCN1C1=CC=C(C=O)C=C1 PFODEVGLOVUVHS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-O 4-methylmorpholin-4-ium Chemical compound C[NH+]1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-O 0.000 description 2
- XNMSAEOZDVATJK-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=C2C(N)=NNC2=NC=C1SC1=CC(F)=CC(F)=C1 XNMSAEOZDVATJK-UHFFFAOYSA-N 0.000 description 2
- LJYGALOYSVFZBF-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfanyl-n-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-1h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1CNC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 LJYGALOYSVFZBF-UHFFFAOYSA-N 0.000 description 2
- BEWMMXCZNODTAZ-UHFFFAOYSA-N 5-[(3,5-difluorophenyl)methyl]-1h-pyrazolo[4,3-b]pyridin-3-amine Chemical compound N1=C2C(N)=NNC2=CC=C1CC1=CC(F)=CC(F)=C1 BEWMMXCZNODTAZ-UHFFFAOYSA-N 0.000 description 2
- VGWDPJMGTMXJIJ-UHFFFAOYSA-N 5-iodo-2-methylsulfanyl-6-oxo-1h-pyridine-3-carbonitrile Chemical compound CSC1=NC(O)=C(I)C=C1C#N VGWDPJMGTMXJIJ-UHFFFAOYSA-N 0.000 description 2
- HSSNFLZQIPOZRO-UHFFFAOYSA-N 6-(3,5-dichlorophenyl)sulfanyl-3-nitropyridine-2-carbonitrile Chemical compound N1=C(C#N)C([N+](=O)[O-])=CC=C1SC1=CC(Cl)=CC(Cl)=C1 HSSNFLZQIPOZRO-UHFFFAOYSA-N 0.000 description 2
- YRFSPIXYUZDAAR-UHFFFAOYSA-N 6-(3,5-difluoro-n-methylanilino)-2-methylsulfanylpyridine-3-carbonitrile Chemical compound C1=C(C#N)C(SC)=NC(N(C)C=2C=C(F)C=C(F)C=2)=C1 YRFSPIXYUZDAAR-UHFFFAOYSA-N 0.000 description 2
- IQPPCENBKPZGQL-UHFFFAOYSA-N 6-(3,5-difluoroanilino)-3-nitropyridine-2-carbonitrile Chemical compound N1=C(C#N)C([N+](=O)[O-])=CC=C1NC1=CC(F)=CC(F)=C1 IQPPCENBKPZGQL-UHFFFAOYSA-N 0.000 description 2
- WDUYGQZRZXAAGJ-UHFFFAOYSA-N 6-amino-2-methylsulfanylpyridine-3-carbonitrile Chemical compound CSC1=NC(N)=CC=C1C#N WDUYGQZRZXAAGJ-UHFFFAOYSA-N 0.000 description 2
- ONGQTMGRJGAOHG-UHFFFAOYSA-N 6-amino-5-iodo-2-methylsulfanylpyridine-3-carbonitrile Chemical compound CSC1=NC(N)=C(I)C=C1C#N ONGQTMGRJGAOHG-UHFFFAOYSA-N 0.000 description 2
- XHSOTQAXOCJEBS-UHFFFAOYSA-N 6-chloro-3-nitropyrazine-2-carbonitrile Chemical class [O-][N+](=O)C1=NC=C(Cl)N=C1C#N XHSOTQAXOCJEBS-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 208000031264 Nerve root compression Diseases 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- KTFXBCVLEMBPGH-UHFFFAOYSA-M [Cl-].FC1=CC(F)=CC(C[Zn+])=C1 Chemical compound [Cl-].FC1=CC(F)=CC(C[Zn+])=C1 KTFXBCVLEMBPGH-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- KEXGUJMBPOYKBG-UHFFFAOYSA-N ethyl 2-chloro-5-chlorosulfonylpyridine-3-carboxylate Chemical class CCOC(=O)C1=CC(S(Cl)(=O)=O)=CN=C1Cl KEXGUJMBPOYKBG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- INCSQLZZXBPATR-UHFFFAOYSA-N methyl 3-aminopyrazine-2-carboxylate Chemical class COC(=O)C1=NC=CN=C1N INCSQLZZXBPATR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- RUAZKOVTMSAJDH-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)sulfamoyl]-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzamide Chemical compound C1CN(C)CCN1C(C=C1N(C2CCOCC2)C(=O)C(F)(F)F)=CC=C1C(=O)NC1=NNC2=NC=C(S(=O)(=O)NC=3C=C(F)C=C(F)C=3)C=C12 RUAZKOVTMSAJDH-UHFFFAOYSA-N 0.000 description 2
- BYDOOCPUDCJBNN-UHFFFAOYSA-N n-[5-[2-(3,5-difluorophenyl)ethynyl]-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC1=NNC2=NC=C(C#CC=3C=C(F)C=C(F)C=3)C=C12 BYDOOCPUDCJBNN-UHFFFAOYSA-N 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 150000002940 palladium Chemical class 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 2
- 229910000367 silver sulfate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical class CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 239000011135 tin Substances 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HYAVEDMFTNAZQE-UHFFFAOYSA-N (benzyldiselanyl)methylbenzene Chemical compound C=1C=CC=CC=1C[Se][Se]CC1=CC=CC=C1 HYAVEDMFTNAZQE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- DBXNGZCLOOGZEW-UHFFFAOYSA-N 1-(2-bromo-2-phenylethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CC(Br)C=2C=CC=CC=2)=C1 DBXNGZCLOOGZEW-UHFFFAOYSA-N 0.000 description 1
- HUJDWVCICJKNQJ-UHFFFAOYSA-N 1-(4-isocyanatophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(N=C=O)C=C1 HUJDWVCICJKNQJ-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical group C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- MJEPPEQNLZSPAP-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridin-3-amine Chemical class C1=CN=C2C(N)=NNC2=C1 MJEPPEQNLZSPAP-UHFFFAOYSA-N 0.000 description 1
- FVJBHWZOURTPME-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridazin-3-amine Chemical class C1=NN=C2C(N)=NNC2=C1 FVJBHWZOURTPME-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- BICHBFCGCJNCAT-UHFFFAOYSA-N 2,4-difluorobenzenethiol Chemical compound FC1=CC=C(S)C(F)=C1 BICHBFCGCJNCAT-UHFFFAOYSA-N 0.000 description 1
- IXJUKNQCZOUQQC-UHFFFAOYSA-N 2-(2-fluoroethoxy)-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]benzoic acid Chemical compound C1CN(C)CCC1N1CCN(C=2C=C(OCCF)C(C(O)=O)=CC=2)CC1 IXJUKNQCZOUQQC-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LGJSPTFUIMJKTA-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1CC1=CC(F)=CC(F)=C1 LGJSPTFUIMJKTA-UHFFFAOYSA-N 0.000 description 1
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 1
- PXRFWOKUSRKWBQ-UHFFFAOYSA-N 2-chloro-5-(phenylsulfamoyl)pyridine-3-carboxamide Chemical class N1=C(Cl)C(C(=O)N)=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 PXRFWOKUSRKWBQ-UHFFFAOYSA-N 0.000 description 1
- CJMKBNLIAVFWJM-UHFFFAOYSA-N 2-chloro-5-(phenylsulfamoyl)pyridine-3-carboxylic acid Chemical class N1=C(Cl)C(C(=O)O)=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 CJMKBNLIAVFWJM-UHFFFAOYSA-N 0.000 description 1
- LPZQFYVQHSUQNF-UHFFFAOYSA-N 2-chloro-5-[(3,5-difluorophenyl)sulfamoyl]pyridine-3-carboxylic acid Chemical compound N1=C(Cl)C(C(=O)O)=CC(S(=O)(=O)NC=2C=C(F)C=C(F)C=2)=C1 LPZQFYVQHSUQNF-UHFFFAOYSA-N 0.000 description 1
- LZTZZRPMYAKSFU-UHFFFAOYSA-N 2-chloro-5-chlorosulfonylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(S(Cl)(=O)=O)=CN=C1Cl LZTZZRPMYAKSFU-UHFFFAOYSA-N 0.000 description 1
- YPSYBQCVDAJOAM-UHFFFAOYSA-N 2-chloro-6-[(3,5-difluorophenyl)methyl]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC(CC=2N=C(Cl)C(C#N)=CC=2)=C1 YPSYBQCVDAJOAM-UHFFFAOYSA-N 0.000 description 1
- BHPYMZQTCPRLNR-UHFFFAOYSA-N 2-cyanoethanethioamide Chemical compound NC(=S)CC#N BHPYMZQTCPRLNR-UHFFFAOYSA-N 0.000 description 1
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 description 1
- AOCSJJIMCMXDDG-UHFFFAOYSA-N 3,5-dichloro-2-nitropyrazine Chemical class [O-][N+](=O)C1=NC=C(Cl)N=C1Cl AOCSJJIMCMXDDG-UHFFFAOYSA-N 0.000 description 1
- WRXIPCQPHZMXOO-UHFFFAOYSA-N 3,5-dichlorobenzenethiol Chemical compound SC1=CC(Cl)=CC(Cl)=C1 WRXIPCQPHZMXOO-UHFFFAOYSA-N 0.000 description 1
- LFYVNHDFVIPZHV-UHFFFAOYSA-N 3,5-difluorobenzenethiol Chemical compound FC1=CC(F)=CC(S)=C1 LFYVNHDFVIPZHV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NZBQURHUOCWMNQ-UHFFFAOYSA-N 3-amino-6-[(3,5-difluorophenyl)methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(N)=CC=C1CC1=CC(F)=CC(F)=C1 NZBQURHUOCWMNQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SXJDZYIIHRCJGR-UHFFFAOYSA-N 3-nitro-6-sulfanylidene-1h-pyrazine-2-carbonitrile Chemical class [O-][N+](=O)C=1N=CC(=S)NC=1C#N SXJDZYIIHRCJGR-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- JHVKFHDSZWQIFF-UHFFFAOYSA-N 4,4,5,5-tetramethyl-3-(4,4,5,5-tetramethyldioxaborolan-3-yl)dioxaborolane Chemical compound CC1(C)C(C)(C)OOB1B1C(C)(C)C(C)(C)OO1 JHVKFHDSZWQIFF-UHFFFAOYSA-N 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- FDNXQCAFVGNIPT-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C(N(C2CCOCC2)C(=O)C(F)(F)F)=C1 FDNXQCAFVGNIPT-UHFFFAOYSA-N 0.000 description 1
- FKERHSPGYLZIDP-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl-methylamino]-2-[2-fluoroethyl-(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound CN(C)CCCN(C)C1=CC=C(C(O)=O)C(N(CCF)C(=O)C(F)(F)F)=C1 FKERHSPGYLZIDP-UHFFFAOYSA-N 0.000 description 1
- LPTRHISTMVJAGX-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl-methylamino]-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound CN(C)CCCN(C)C1=CC=C(C(O)=O)C(N(C2CCOCC2)C(=O)C(F)(F)F)=C1 LPTRHISTMVJAGX-UHFFFAOYSA-N 0.000 description 1
- JZUHRPMBVSKAQQ-UHFFFAOYSA-N 4-methylsulfanyl-6-oxo-1h-pyridazine-3-carbonitrile Chemical class CSC1=CC(O)=NN=C1C#N JZUHRPMBVSKAQQ-UHFFFAOYSA-N 0.000 description 1
- SVSBNSLUTSGNME-UHFFFAOYSA-N 4-methylsulfanyl-6-oxo-1h-pyridine-3-carbonitrile Chemical compound CSC1=CC(O)=NC=C1C#N SVSBNSLUTSGNME-UHFFFAOYSA-N 0.000 description 1
- KSAZYTFFRSXHLP-UHFFFAOYSA-N 5-(3,5-difluorophenyl)sulfonyl-2h-pyrazolo[3,4-b]pyrazin-3-amine Chemical compound N1=C2C(N)=NNC2=NC=C1S(=O)(=O)C1=CC(F)=CC(F)=C1 KSAZYTFFRSXHLP-UHFFFAOYSA-N 0.000 description 1
- YXWLEUCOZAOKNX-UHFFFAOYSA-N 5-benzyl-2-nitropyridine-3-carbonitrile Chemical class C1=C(C#N)C([N+](=O)[O-])=NC=C1CC1=CC=CC=C1 YXWLEUCOZAOKNX-UHFFFAOYSA-N 0.000 description 1
- GUSUHJNWILBQNV-UHFFFAOYSA-N 5-chloro-2-nitropyridine-3-carbonitrile Chemical compound [O-][N+](=O)C1=NC=C(Cl)C=C1C#N GUSUHJNWILBQNV-UHFFFAOYSA-N 0.000 description 1
- DMQTXELGRVDQPY-UHFFFAOYSA-N 5-cyano-6-methylsulfanylpyridine-3-carboxylic acid Chemical group CSC1=NC=C(C(O)=O)C=C1C#N DMQTXELGRVDQPY-UHFFFAOYSA-N 0.000 description 1
- YKRKKFQQFSQVCW-UHFFFAOYSA-N 5-iodo-6-methoxy-2-methylsulfonylpyridine-3-carbonitrile Chemical compound COC1=NC(S(C)(=O)=O)=C(C#N)C=C1I YKRKKFQQFSQVCW-UHFFFAOYSA-N 0.000 description 1
- DMLPQTWDFZCDTJ-UHFFFAOYSA-N 5-methoxypyridine-3-carbonitrile Chemical compound COC1=CN=CC(C#N)=C1 DMLPQTWDFZCDTJ-UHFFFAOYSA-N 0.000 description 1
- MZRUFMBFIKGOAL-UHFFFAOYSA-N 5-nitro-1h-pyrazole Chemical class [O-][N+](=O)C1=CC=NN1 MZRUFMBFIKGOAL-UHFFFAOYSA-N 0.000 description 1
- YYBIEWNTHVYNHE-UHFFFAOYSA-N 6-(2,4-difluoro-n-methylanilino)-2-methylsulfanylpyridine-3-carbonitrile Chemical compound C1=C(C#N)C(SC)=NC(N(C)C=2C(=CC(F)=CC=2)F)=C1 YYBIEWNTHVYNHE-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- WGUBQNSZEHNKFH-UHFFFAOYSA-N 6-[(3,5-difluorophenyl)methyl]-3-nitropyridine-2-carbonitrile Chemical compound N1=C(C#N)C([N+](=O)[O-])=CC=C1CC1=CC(F)=CC(F)=C1 WGUBQNSZEHNKFH-UHFFFAOYSA-N 0.000 description 1
- LMRYVMLKXMJWNL-UHFFFAOYSA-N 6-amino-5-iodo-2-methylsulfonylpyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C(I)C=C1C#N LMRYVMLKXMJWNL-UHFFFAOYSA-N 0.000 description 1
- AOMBSGDJMMMUNI-UHFFFAOYSA-N 6-benzyl-3-nitropyrazine-2-carbonitrile Chemical class N1=C(C#N)C([N+](=O)[O-])=NC=C1CC1=CC=CC=C1 AOMBSGDJMMMUNI-UHFFFAOYSA-N 0.000 description 1
- SCZZEMIFQWCCGY-UHFFFAOYSA-N 6-benzyl-3-nitropyridine-2-carbonitrile Chemical class N1=C(C#N)C([N+](=O)[O-])=CC=C1CC1=CC=CC=C1 SCZZEMIFQWCCGY-UHFFFAOYSA-N 0.000 description 1
- ZGCFHYKQHHBJJZ-UHFFFAOYSA-N 6-chloro-1h-pyrazolo[4,3-c]pyridin-3-amine Chemical class ClC1=NC=C2C(N)=NNC2=C1 ZGCFHYKQHHBJJZ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006509 Congenital Pain Insensitivity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000870659 Crassula perfoliata var. minor Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NXWFYDFNTNZIGI-UHFFFAOYSA-N OBOCC1=CC=CC=C1 Chemical compound OBOCC1=CC=CC=C1 NXWFYDFNTNZIGI-UHFFFAOYSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- SAQSTQBVENFSKT-UHFFFAOYSA-M TCA-sodium Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)Cl SAQSTQBVENFSKT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- TUXYPYQILWEWPJ-UHFFFAOYSA-N [1,3]dioxolo[4,5-c]pyridine Chemical compound C1=NC=C2OCOC2=C1 TUXYPYQILWEWPJ-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000037738 autosomal recessive channelopathy-associated congenital insensitivity to pain Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KGLYSXGHNGYWSL-UHFFFAOYSA-N chloromethylbenzene;zinc Chemical compound [Zn].ClCC1=CC=CC=C1 KGLYSXGHNGYWSL-UHFFFAOYSA-N 0.000 description 1
- LIQBAAKGMWRWPS-UHFFFAOYSA-M chlorozinc(1+);methanidylbenzene Chemical compound [Zn+]Cl.[CH2-]C1=CC=CC=C1 LIQBAAKGMWRWPS-UHFFFAOYSA-M 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- XEDHNTPQPKCZSF-UHFFFAOYSA-N diethyl 2-(4-fluoro-2-nitrophenyl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=C(F)C=C1[N+]([O-])=O XEDHNTPQPKCZSF-UHFFFAOYSA-N 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- PGFWCWVVIAJUKT-UHFFFAOYSA-N diethyl 2-[4-(4-methylpiperazin-1-yl)-2-nitrophenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OCC)C(=O)OCC)=CC=C1N1CCN(C)CC1 PGFWCWVVIAJUKT-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- LYGPATUMODNSAM-ONEGZZNKSA-N ethyl (e)-3-(4-aminopyridin-3-yl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CN=CC=C1N LYGPATUMODNSAM-ONEGZZNKSA-N 0.000 description 1
- KNTPUWHHNMODOA-UHFFFAOYSA-N ethyl 5-cyano-6-methylsulfanylpyridine-3-carboxylate Chemical class CCOC(=O)C1=CN=C(SC)C(C#N)=C1 KNTPUWHHNMODOA-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- UEXCJVNBTNXOEH-OUBTZVSYSA-N ethynylbenzene Chemical class [13CH]#CC1=CC=CC=C1 UEXCJVNBTNXOEH-OUBTZVSYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical class 0.000 description 1
- ZYXBIOIYWUIXSM-UHFFFAOYSA-N furo[2,3-c]pyridine Chemical compound C1=NC=C2OC=CC2=C1 ZYXBIOIYWUIXSM-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 201000000887 hereditary sensory and autonomic neuropathy type 5 Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- IMCCZKHIPVEUEI-UHFFFAOYSA-N n,n-difluoroaniline Chemical compound FN(F)C1=CC=CC=C1 IMCCZKHIPVEUEI-UHFFFAOYSA-N 0.000 description 1
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical group CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
- VNTDGIJKOWGCGP-UHFFFAOYSA-N n-(5-iodo-1-tritylpyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC1=NN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=NC=C(I)C=C12 VNTDGIJKOWGCGP-UHFFFAOYSA-N 0.000 description 1
- RQOOJWGFSPUOKJ-UHFFFAOYSA-N n-(5-iodo-2h-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC1=NNC2=NC=C(I)C=C12 RQOOJWGFSPUOKJ-UHFFFAOYSA-N 0.000 description 1
- ZQKDPKODEFRUEN-UHFFFAOYSA-N n-[5-(3,5-difluoroanilino)-1-tritylpyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NN(C(C=3C=CC=CC=3)(C=3C=CC=CC=3)C=3C=CC=CC=3)C1=NC=C2NC1=CC(F)=CC(F)=C1 ZQKDPKODEFRUEN-UHFFFAOYSA-N 0.000 description 1
- QLTWJYWRIYEPDI-UHFFFAOYSA-N n-[5-(3,5-difluoroanilino)-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=NC=C2NC1=CC(F)=CC(F)=C1 QLTWJYWRIYEPDI-UHFFFAOYSA-N 0.000 description 1
- JGPJNEQDNBDCOJ-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-yl]-2-(4-nitrophenyl)acetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(=O)NC(C1=C2)=NNC1=NC=C2SC1=CC(F)=CC(F)=C1 JGPJNEQDNBDCOJ-UHFFFAOYSA-N 0.000 description 1
- DNSGDBHRFQIANM-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC1=C2C=C(SC=3C=C(F)C=C(F)C=3)C=NC2=NN1 DNSGDBHRFQIANM-UHFFFAOYSA-N 0.000 description 1
- MRIJZDWNMLZNGL-UHFFFAOYSA-N n-[5-(3,5-difluorophenyl)sulfanyl-6-methoxy-2h-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1=2C=C(SC=3C=C(F)C=C(F)C=3)C(OC)=NC=2NN=C1NC(=O)C1=CC=C(N2CCN(C)CC2)C=C1NC1CCOCC1 MRIJZDWNMLZNGL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- UEXCJVNBTNXOEH-UHFFFAOYSA-N phenyl acethylene Natural products C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- NVHXMNNCHAFIHX-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=C=N[N]1 NVHXMNNCHAFIHX-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- JBDKAABFESSFMV-UHFFFAOYSA-N pyrrolo[1,2-a]pyrimidine Chemical compound N1=CC=CN2C=CC=C21 JBDKAABFESSFMV-UHFFFAOYSA-N 0.000 description 1
- RIEKLTCRUGDAPM-UHFFFAOYSA-N pyrrolo[1,2-c]pyrimidine Chemical compound C1=CN=CN2C=CC=C21 RIEKLTCRUGDAPM-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- PBUSFCZVNOIGLX-UHFFFAOYSA-N tert-butyl 4-(1-methylpiperidin-4-yl)-2-[oxan-4-yl-(2,2,2-trifluoroacetyl)amino]benzoate Chemical compound C1CN(C)CCC1C1=CC=C(C(=O)OC(C)(C)C)C(N(C2CCOCC2)C(=O)C(F)(F)F)=C1 PBUSFCZVNOIGLX-UHFFFAOYSA-N 0.000 description 1
- WFQHGCOHRFRRHU-UHFFFAOYSA-N tert-butyl 4-bromo-2-nitrobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(Br)C=C1[N+]([O-])=O WFQHGCOHRFRRHU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical class FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Forbindelse med følgende almene formel (I):
(i) eller et farmaceutisk acceptabelt salt eller solvat af samme, en tautomer af samme eller en stereoisomer eller blanding af stereoisomerer af samme i et hvilket som helst forhold, såsom en blanding af enantiomerer, især en race-misk blanding, hvor: - Yi og Y4 hver, uafhængigt af hinanden, betegner en CH-gruppe eller et nitrogenatom, på betingelse af at mindst en af Y1 og Y4 betegner et nitrogenatom, - Y2 betegner en C-X-Ar-gruppe, - Y3 betegner en C-W-gruppe, - Ar betegner en aryl- eller heteroarylgruppe eventuelt substitueret med en eller flere grupper udvalgt blandt et halogenatom, (CrC6)alkyl, (Cr C6)haloalkyl, (CrC6)haloalkoxy, (CrC6)halothioalkoxy, CN, N02, ORn, SR12, NR13R14, CO2R15J CONR16Ri7, SO2R181 SO2NR19R20! COR21, NR22COR23, NR24SO2R25 og R26NR27R28 og/eller eventuelt fusioneret på en heterocyklus, - X betegner en divalent gruppe udvalgt blandt O, S, S(O), S(0)2, NR4, S(NR4), S(0)(NR4), S(0)2(NR4), NR4S, NR4S(0), NR4S(0)2j ch2, ch2s, CH2S(0), CH2S(0)2, SCH2j S(0)CH2, S(0)2CH2j CH2CH2, CH=CH, c=c, ch2o, och2, NR4CH2 og ch2nr4, - W betegner en R5-, SR5-, OR5- eller NRsRø-gruppe, - U betegner en CH2- eller NH-gruppe, et eller flere hydrogenatomer, der kan erstattes af en (CrC6)alkylgruppe, - V betegner C(O), C(S) eller CH2, - n betegner 0 eller 1, - Ri betegner et hydrogenatom eller en OR7- eller NR7Rs-gruppe, - R2 betegner et hydrogenatom, en eventuelt substitueret heterocyklus, N02, ORg eller NRgR-io, - R3, R4, R11 til R25 og R27 til R28 hver, uafhængigt af hinanden, betegner et hydrogenatom eller en (CrC6)alkylgruppe, - R5 og R6 hver, uafhængigt af hinanden, betegner et hydrogenatom eller en (CrC6)alkyl, en eventuelt substitueret aryl eller eventuelt substitueret benzyl-gruppe, - R7, R8j Rg and R™ hver, uafhængigt af hinanden, betegner et hydrogenatom eller en eventuelt substitueret (CrC6)alkyl eller (C3-Ci2)cycloalkylgruppe eller en eventuelt substitueret heterocyklus, og - R26 betegner en (CrC6)alkylgruppe, til anvendelse ved behandling eller forebyggelse af smerte.
2. Forbindelse til anvendelse ifølge krav 1, kendetegnet ved, at smerten er en nociceptiv smerte, en inflammatorisk smerte, en neuropatisk smerte, en idiopatisk smerte eller en psykogen smerte, fortrinsvis en inflammatorisk smerte eller neuropatisk smerte.
3. Forbindelse ifølge krav 1 eller 2, hvor smerten skyldes cancer, en nervebeskadigelse eller reumatiske sygdomme.
4. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved, at: - Y1= CH eller N, og - Y4 = N.
5. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved, at: - Yi betegner en CH-gruppe, og - Y4 betegner et nitrogenatom.
6. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved, at X betegner en divalent gruppe udvalgt blandt S, S(O), S(0)2, NR4, CH2, CH2S, CH2S(0), CH2S(0)2, CH2O, CH2NR4, NHS(0)2j SCH2, S(0)CH2, S(0)2CH2, S(0)2NH, och2, nr4ch2, ch2ch2, CFI=CH og C=C; især blandt S, S(O), S(0)2, NR4, CH2, SCH2, S(0)CH2, S(0)2CH2, S(0)2NH, CH2CH2j C=C, OCH2 og NR4CH2; især blandt S, S(0)2, CH2, SCH2, S(0)2CH2j S(0)2NH, CH2CH2 og C=C, hvor det første atom af disse grupper er bundet til atom C i kæden C-X-Ar.
7. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 6, kendetegnet ved, at Ar betegner en arylgruppe, såsom phenyl, eventuelt substitueret med en eller flere grupper udvalgt blandt et halogenatom, (Cr C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)haloalkoxy, (CrC6)halothioalkoxy, CN, N02, ORii, SRi2, NRi3Ri4, C02Ri5 og CONR16R17, S02Ris, S02NRigR2o, COR2i, NR22COR23 eller NR24S02R2s; eller en pyridingruppe.
8. Forbindelse til anvendelse ifølge krav 7, kendetegnet ved, at Ar betegner en gruppe udvalgt blandt følgende grupper:
9. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 8, kendetegnet ved, at W betegner en R5-, SR5-, OR5- eller NRsRe-gruppe, idet R5 og R6, uafhængigt af hinanden, betegner et hydrogenatom eller en (Cr C6)alkylgruppe.
10. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 9, kendetegnet ved, at: - r3=h, - U=CH2 eller NH, - V=C(0) eller C(S), og især C(0), og - n=0 eller 1, og især 0.
11. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 10, kendetegnet ved, at Ri betegner et hydrogenatom eller en NR7Rs-gruppe, idet R7 betegner et hydrogenatom, og R8 betegner en eventuelt substitueret (C3-Ci2)cycloalkylgruppe eller en eventuelt substitueret heterocyklus.
12. Forbindelse til anvendelse ifølge krav 11, kendetegnet ved, at Ri beteaner en af følaende arupper: H,
13. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 12, kendetegnet ved, at R2 betegner N02, NRgR-ιο eller en heterocyklus eventuelt substitueret med (CrC6)alkyl eller NH2.
14. Forbindelse til anvendelse ifølge krav 13, kendetegnet ved, at R2 betegner en af følgende grupper: NH2, NH(CH2)3NMe2, NMe(CH2)3NMe2, N02,
og
15. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 14, kendetegnet ved, at den er valgt blandt følgende forbindelser:
16. Farmaceutisk sammensætning indeholdende mindst et farmaceutisk acceptabelt hjælpestof og en forbindelse ifølge et hvilket som helst af kravene 1 til 15 som aktiv bestanddel, til anvendelse som en behandling eller forebyg- gelse eller af smerte.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305922.2A EP2689778A1 (en) | 2012-07-27 | 2012-07-27 | Derivatives of azaindoles or diazaindoles for treating pain |
PCT/EP2013/065907 WO2014016433A1 (en) | 2012-07-27 | 2013-07-29 | Derivatives of azaindazole or diazaindazole type for treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2877177T3 true DK2877177T3 (da) | 2017-02-06 |
Family
ID=48948392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13745813.9T DK2877177T3 (da) | 2012-07-27 | 2013-07-29 | Derivater af azaindazol- eller diazaindazol-type til behandling af smerte |
Country Status (29)
Country | Link |
---|---|
US (1) | US9381195B2 (da) |
EP (2) | EP2689778A1 (da) |
JP (2) | JP6456823B2 (da) |
KR (1) | KR102120505B1 (da) |
CN (1) | CN104684554B (da) |
AU (1) | AU2013294920B2 (da) |
BR (1) | BR112015001502B1 (da) |
CA (1) | CA2879595C (da) |
CY (1) | CY1118478T1 (da) |
DK (1) | DK2877177T3 (da) |
ES (1) | ES2612349T3 (da) |
HK (1) | HK1207302A1 (da) |
HR (1) | HRP20170104T1 (da) |
HU (1) | HUE032919T2 (da) |
IL (1) | IL236917A (da) |
LT (1) | LT2877177T (da) |
MA (1) | MA37866B1 (da) |
MX (1) | MX363605B (da) |
MY (1) | MY183398A (da) |
NZ (1) | NZ705253A (da) |
PL (1) | PL2877177T3 (da) |
PT (1) | PT2877177T (da) |
RS (1) | RS55646B1 (da) |
RU (1) | RU2640046C2 (da) |
SI (1) | SI2877177T1 (da) |
TN (1) | TN2015000034A1 (da) |
UA (1) | UA116107C2 (da) |
WO (1) | WO2014016433A1 (da) |
ZA (1) | ZA201501209B (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE057625T2 (hu) | 2008-10-22 | 2022-05-28 | Array Biopharma Inc | TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
WO2015143652A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
EP3204007B1 (en) * | 2014-10-06 | 2023-12-20 | Apm Therapeutics 1, Inc. | Triazolopyridine compounds and methods for the treatment of cystic fibrosis |
TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
WO2016096709A1 (en) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
RU2744852C2 (ru) | 2015-10-26 | 2021-03-16 | Локсо Онколоджи, Инк. | Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы |
WO2017176751A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
JP7443057B2 (ja) | 2016-05-18 | 2024-03-05 | ロクソ オンコロジー, インコーポレイテッド | (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製 |
US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018079759A1 (ja) * | 2016-10-31 | 2018-05-03 | 塩野義製薬株式会社 | TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
KR102653799B1 (ko) * | 2018-05-02 | 2024-04-03 | 제이더블유중외제약 주식회사 | 신규한 헤테로 사이클 유도체 |
KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
CN110105356B (zh) * | 2019-05-31 | 2022-04-01 | 四川国康药业有限公司 | 一种氮杂吲哚类化合物及其制备方法和用途 |
CN110935250A (zh) | 2019-12-10 | 2020-03-31 | 科沃斯机器人股份有限公司 | 空气净化设备 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041525A1 (en) * | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
ES2223863T3 (es) | 2000-06-22 | 2005-03-01 | Pfizer Inc. | Procedimiento para la preparacion de pirazolopirimidinonas. |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
EP1919913A2 (en) * | 2005-08-25 | 2008-05-14 | F.Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
CA2657287A1 (en) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
MX2009006401A (es) | 2006-12-20 | 2009-06-23 | Nerviano Medical Sciences Srl | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. |
WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
WO2008112695A2 (en) * | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
KR101636312B1 (ko) | 2007-07-20 | 2016-07-05 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서 활성인 치환된 인다졸 유도체 |
ES2630026T3 (es) * | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Derivados indazólicos sustituidos activos como inhibidores de cinasa |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
-
2012
- 2012-07-27 EP EP12305922.2A patent/EP2689778A1/en not_active Withdrawn
-
2013
- 2013-07-29 NZ NZ705253A patent/NZ705253A/en unknown
- 2013-07-29 WO PCT/EP2013/065907 patent/WO2014016433A1/en active Application Filing
- 2013-07-29 UA UAA201501614A patent/UA116107C2/uk unknown
- 2013-07-29 PL PL13745813T patent/PL2877177T3/pl unknown
- 2013-07-29 JP JP2015523576A patent/JP6456823B2/ja active Active
- 2013-07-29 EP EP13745813.9A patent/EP2877177B1/en active Active
- 2013-07-29 BR BR112015001502-6A patent/BR112015001502B1/pt active IP Right Grant
- 2013-07-29 RS RS20170095A patent/RS55646B1/sr unknown
- 2013-07-29 HU HUE13745813A patent/HUE032919T2/hu unknown
- 2013-07-29 AU AU2013294920A patent/AU2013294920B2/en active Active
- 2013-07-29 MY MYPI2015700206A patent/MY183398A/en unknown
- 2013-07-29 KR KR1020157004735A patent/KR102120505B1/ko active IP Right Grant
- 2013-07-29 CA CA2879595A patent/CA2879595C/en active Active
- 2013-07-29 ES ES13745813.9T patent/ES2612349T3/es active Active
- 2013-07-29 DK DK13745813.9T patent/DK2877177T3/da active
- 2013-07-29 SI SI201330496A patent/SI2877177T1/sl unknown
- 2013-07-29 LT LTEP13745813.9T patent/LT2877177T/lt unknown
- 2013-07-29 PT PT137458139T patent/PT2877177T/pt unknown
- 2013-07-29 RU RU2015106434A patent/RU2640046C2/ru active
- 2013-07-29 US US14/417,507 patent/US9381195B2/en active Active
- 2013-07-29 CN CN201380049411.3A patent/CN104684554B/zh active Active
- 2013-07-29 MX MX2015001009A patent/MX363605B/es unknown
-
2015
- 2015-01-23 TN TNP2015000034A patent/TN2015000034A1/fr unknown
- 2015-01-25 IL IL236917A patent/IL236917A/en active IP Right Grant
- 2015-02-23 MA MA37866A patent/MA37866B1/fr unknown
- 2015-02-23 ZA ZA2015/01209A patent/ZA201501209B/en unknown
- 2015-08-18 HK HK15107972.0A patent/HK1207302A1/xx unknown
-
2017
- 2017-01-23 CY CY20171100091T patent/CY1118478T1/el unknown
- 2017-01-23 HR HRP20170104TT patent/HRP20170104T1/hr unknown
-
2018
- 2018-10-24 JP JP2018200317A patent/JP6732855B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2877177T3 (da) | Derivater af azaindazol- eller diazaindazol-type til behandling af smerte | |
DK2668184T3 (da) | Derivater af azaindazol- eller diazaindazol-type som medikament | |
US9428510B2 (en) | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk | |
OA17324A (en) | Derivatives of azaindazole or diazaindazole type for treating pain. | |
OA16493A (en) | Derivatives of azaindazole or diazaindazole type as medicament. |